Grade III Dermatitis in a Patient Treated With Paclitaxel and Radiotherapy: Case Report and Review of the Literature

Anna Zygogianni, Konstantinos Gennatas, John Kouvaris, Ioanna Kantzou, Christos Antypas, Maria Tolia, Vassilios Kouloulias


Taxanes, both paclitaxel and doxetaxel are the medication of the future in the management of solid tumors. In high risk breast cancer patients, the combination of concurrent paclitaxel and docetaxel chemotherapy with adjuvant radiotherapy is an attractive option to sequential treatment, with potential for enforcing both local and systemic control. This case report examines the tolerance of such treatment. A 54-year-old Greek woman without a relevant medical history, presented with clinical diagnosed breast cancer staged T4NxM0. Neo-adjuvant chemotherapy was initially administered, and paclitaxel was administered concurrently with radiotherapy in order to achieve local control. During the third cycle of paclitaxel the patient developed grade III dermatitis. The tumor showed a reduction in size by 70%, however, chronic cutaneous and subcutaneous changes have not been accessed. In conclusion, adjuvant breast cancer therapy with concurrent standard dose radiotherapy and paclitaxel (175 mg/m2) every three weeks, should be approached cautiously owing to paclitaxel induced dermatitis.



Paclitaxel; Taxanes; Radiotherapy; Breast cancer; Case report

Full Text: HTML PDF

Browse  Journals  


Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics






World Journal of Oncology, bimonthly, ISSN 1920-4531 (print), 1920-454X (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.